-
Something wrong with this record ?
HE4 and ROMA index in Czech postmenopausal women
Z. Novotny, J. Presl, R. Kucera, O. Topolcan, J. Vrzalova, R. Fuchsova, L. Betincova, Z. Rokyta,
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
22993374
Knihovny.cz E-resources
- MeSH
- Algorithms MeSH
- CA-125 Antigen blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Membrane Proteins blood MeSH
- Ovarian Neoplasms blood MeSH
- Ovarian Diseases blood MeSH
- Postmenopause blood MeSH
- Proteins metabolism MeSH
- Age Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
AIM: The first aim of the project was to evaluate the benefits of the determination of human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index for primary detection of ovarian cancer in a population of Czech women. The second aim was to study the advantages HE4, cancer antigen 125 (CA125) and ROMA index for distinguishing between benign and malignant tumors. Aware of the age distribution of ovarian cancer, we focused on postmenopausal patients. PATIENTS AND METHODS: Our group of patients consisted of 256 females, 21 with ovarian cancer and 235 with benign ovarian tumors. All diagnoses were histologically verified. We determined the serum levels of HE4 and CA125 and calculated the ROMA2 index for postmenopausal women. Serum levels of the analytes were measured using an Architect 1000i instrument. Serum samples were collected prior to surgery or any other form of treatment and the results of the two groups of patients were compared (malignant vs. benign). RESULTS: There was a significant difference in the serum levels for all parameters studied between the groups of patients with malignant and those with benign diagnoses (Wilcoxon test, p<0.0001). When all parameters were evaluated at 95% specificity, the HE4 cut-off was 112 pmol/l at a sensitivity of 71.42%, a positive predictive value (PPV) of 55.56%, a negative predictive value (NPV) of 97.14% and an area under the curve (AUC) of 0.9152. The CA125 cut-off was 81 IU/l at a sensitivity of 80.95%, a PPV of 58.62%, a NPV of 98.23% and an AUC of 0.9731. ROMA2 index had a cut-off 37.70% at a sensitivity of 85.71%, a PPV of 62.06%, a NPV of 98.65% and an AUC of 0.9803. The highest diagnostic efficiency was achieved by the ROMA2 index. CONCLUSION: Determination of HE4 along with CA125 and ROMA2 index calculation is a suitable method for the improvement of the primary detection of ovarian cancer. This approach also improves the differential diagnostic possibilities for distinguishing between malignant and benign tumors.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13012444
- 003
- CZ-PrNML
- 005
- 20130408112238.0
- 007
- ta
- 008
- 130404s2012 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)22993374
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Novotny, Zdenek $u Department of Gynecology and Obstetrics, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
- 245 10
- $a HE4 and ROMA index in Czech postmenopausal women / $c Z. Novotny, J. Presl, R. Kucera, O. Topolcan, J. Vrzalova, R. Fuchsova, L. Betincova, Z. Rokyta,
- 520 9_
- $a AIM: The first aim of the project was to evaluate the benefits of the determination of human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) index for primary detection of ovarian cancer in a population of Czech women. The second aim was to study the advantages HE4, cancer antigen 125 (CA125) and ROMA index for distinguishing between benign and malignant tumors. Aware of the age distribution of ovarian cancer, we focused on postmenopausal patients. PATIENTS AND METHODS: Our group of patients consisted of 256 females, 21 with ovarian cancer and 235 with benign ovarian tumors. All diagnoses were histologically verified. We determined the serum levels of HE4 and CA125 and calculated the ROMA2 index for postmenopausal women. Serum levels of the analytes were measured using an Architect 1000i instrument. Serum samples were collected prior to surgery or any other form of treatment and the results of the two groups of patients were compared (malignant vs. benign). RESULTS: There was a significant difference in the serum levels for all parameters studied between the groups of patients with malignant and those with benign diagnoses (Wilcoxon test, p<0.0001). When all parameters were evaluated at 95% specificity, the HE4 cut-off was 112 pmol/l at a sensitivity of 71.42%, a positive predictive value (PPV) of 55.56%, a negative predictive value (NPV) of 97.14% and an area under the curve (AUC) of 0.9152. The CA125 cut-off was 81 IU/l at a sensitivity of 80.95%, a PPV of 58.62%, a NPV of 98.23% and an AUC of 0.9731. ROMA2 index had a cut-off 37.70% at a sensitivity of 85.71%, a PPV of 62.06%, a NPV of 98.65% and an AUC of 0.9803. The highest diagnostic efficiency was achieved by the ROMA2 index. CONCLUSION: Determination of HE4 along with CA125 and ROMA2 index calculation is a suitable method for the improvement of the primary detection of ovarian cancer. This approach also improves the differential diagnostic possibilities for distinguishing between malignant and benign tumors.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a algoritmy $7 D000465
- 650 _2
- $a antigen CA-125 $x krev $7 D018394
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a membránové proteiny $x krev $7 D008565
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nemoci ovaria $x krev $7 D010049
- 650 _2
- $a nádory vaječníků $x krev $7 D010051
- 650 _2
- $a postmenopauza $x krev $7 D017698
- 650 _2
- $a proteiny $x metabolismus $7 D011506
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Presl, Jiri $u -
- 700 1_
- $a Kucera, Radek $u -
- 700 1_
- $a Topolcan, Ondrej $u -
- 700 1_
- $a Vrzalova, Jindra $u -
- 700 1_
- $a Fuchsova, Radka $u -
- 700 1_
- $a Betincova, Lucie $u -
- 700 1_
- $a Rokyta, Zdenek $u -
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 32, č. 9 (2012), s. 4137-40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22993374 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130404 $b ABA008
- 991 __
- $a 20130408112504 $b ABA008
- 999 __
- $a ok $b bmc $g 975642 $s 810725
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 32 $c 9 $d 4137-40 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20130404